Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 2/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12503417 | 0.87 | AXL (0.60) | PDGFRBPDGFRAMETFGFR2SRC | |
| SCHEMBL25626491 | 0.87 | AXL (0.51) | PDGFRAMETSRCTGFBR1 | |
| SCHEMBL21185496 | 0.82 | PDGFRA (0.58) | PDGFRBPDGFRAFGFR2SRCTGFBR1 | |
| SCHEMBL30106509 | 0.81 | MET (0.58) | PDGFRBPDGFRAMETFGFR2EGFR | |
| SCHEMBL371742 | 0.81 | MET (0.58) | PDGFRBPDGFRAMETFGFR2EGFR | |
| SCHEMBL13955465 | 0.80 | FGFR2 (0.58) | PDGFRBPDGFRAMETFGFR2SRC | |
| SCHEMBL23158610 | 0.79 | FGFR2 (0.58) | PDGFRBPDGFRAMETFGFR2 | |
| SCHEMBL21769162 | 0.78 | MET (0.56) | PDGFRBPDGFRAMETFGFR2 | |
| SCHEMBL371888 | 0.78 | PDGFRA (0.60) | PDGFRBPDGFRAMET | |
| SCHEMBL30106564 | 0.78 | PDGFRA (0.60) | PDGFRBPDGFRAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRB 90/4885PDGFRA 182/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.